Last reviewed · How we verify
Roctavian — Competitive Intelligence Brief
marketed
Rare Disease
Gene therapy
Live · refreshed every 30 min
Target snapshot
Roctavian (VALOCTOCOGENE ROXAPARVOVEC) — BioMarin International Limited. Roctavian introduces a functional copy of the F8 gene into cells to produce factor VIII protein.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Roctavian TARGET | VALOCTOCOGENE ROXAPARVOVEC | BioMarin International Limited | marketed | 2022-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Roctavian — Competitive Intelligence Brief. https://druglandscape.com/ci/valoctocogene-roxaparvovec. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing